USPTO serial 97767968
Reviewed by CopyMark Law Group
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Christina M. Licursi
Christina M. Licursi WOLF, GREENFIELD & SACKS, P.C.600 ATLANTIC AVENUEBOSTON, MA 02210United States| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Biological and chemical agents, namely, chemical preparations for scientific and research use; synthetic nucleic acids other than for medical or veterinary purposes; chemically modified nucleic acids, other than for medical or veterinary purposes; chemicals for use in biotherapeutics in the biochemical and chemical industries and excluding medical and veterinary purpose; biological preparations for use in industry and science; chemical agents, namely, chemical preparations for analyses in laboratories, other than for medical or veterinary purposes | ACTIVE | Jan 22, 2025 |
| 005 | Pharmaceutical, therapeutic pharmaceuticals, and biopharmaceutical preparations and agents for the treatment of a variety of human and animal diseases and disorders, namely, enzyme deficiency diseases and disorders, genetic diseases and disorders, hepatic diseases and disorders, metabolic diseases and disorders, neurological diseases and disorders, neuromuscular diseases and disorders, and rare diseases and disorders; nucleic acid-based therapeutic pharmaceuticals and therapeutic agents for the treatment of a variety of human and animal diseases and disorders, namely, enzyme deficiency diseases and disorders, genetic diseases and disorders, hepatic diseases and disorders, metabolic diseases and disorders, neurological diseases and disorders, neuromuscular diseases and disorders, and rare diseases and disorders; chemicals for use in therapeutic product development and manufacturing processes in the medical field | ACTIVE | Jan 22, 2025 |
| 042 | Research and development of pharmaceutical, therapeutic and biopharmaceutical preparations and agents for the treatment of a variety of human and animal diseases and disorders, namely, enzyme deficiency diseases and disorders, genetic diseases and disorders, hepatic diseases and disorders, metabolic diseases and disorders, neurological diseases and disorders, neuromuscular diseases and disorders, and rare diseases and disorders; research and development of technology in the field of pharmaceutical, therapeutic and biopharmaceutical preparations and agents; pharmaceutical drug development and drug discovery services; pharmaceutical research and analysis services using machine learning analytics relating to pharmaceutical drug development; scientific research, pharmaceutical research, medical research, technical consultation, and product development for others in the field of biotechnology and development of pharmaceutical, therapeutic, and biopharmaceutical preparations and agents | ACTIVE | Dec 26, 2019 |
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
| Date | Code | Event | What it means |
|---|---|---|---|
| Dec 23, 2025 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Dec 23, 2025 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Dec 3, 2025 | SUNA | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | — |
| Dec 3, 2025 | CNPR | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | — |
| Oct 18, 2025 | SUPC | STATEMENT OF USE PROCESSING COMPLETE | — |
| Oct 18, 2025 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| May 14, 2025 | IUAF | USE AMENDMENT FILED | — |
| May 14, 2025 | EISU | TEAS STATEMENT OF USE RECEIVED | The applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action. |
| Nov 6, 2024 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Nov 6, 2024 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Nov 6, 2024 | EXT1 | SOU EXTENSION 1 FILED | — |
| Nov 6, 2024 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| May 14, 2024 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Mar 19, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Mar 19, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Feb 28, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Feb 28, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Feb 13, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Feb 13, 2024 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Feb 13, 2024 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Feb 13, 2024 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Feb 13, 2024 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Feb 6, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 5, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 5, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 15, 2023 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 15, 2023 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 15, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 23, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 14, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jan 28, 2023 | NWAP | NEW APPLICATION ENTERED | — |